Lupin receives USFDA's approval for generic version of AbbVie’s AndroGel

17 Apr 2018 Evaluate

Lupin has received tentative approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation) from the United States Food and Drug Administration (USFDA) to market a generic version of AbbVie’s AndroGel, 1.62%.

Lupin’s Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation) is the generic equivalent of AbbVie’s AndroGel, 1.62%.  Lupin’s Testosterone Gel is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation) had annual sales of around $ 956.9 million in the US (IQVIA MAT January 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2052.05 -19.30 (-0.93%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×